| SC 13G | 2024-04-08 | Paradigm Biocapital Advisors LP | Y-mAbs Therapeutics, Inc. | 2,198,312 | 5.0% | EDGAR |
| SC 13G/A | 2024-02-14 | WG Biotech ApS | Y-mAbs Therapeutics, Inc. | 4,559,233 | 10.4% | EDGAR |
| SC 13G/A | 2024-02-13 | HBM Healthcare Investments (Cayman) Ltd. | Y-mAbs Therapeutics, Inc. | 3,297,800 | 7.6% | EDGAR |
| SC 13G/A | 2024-02-13 | VANGUARD GROUP INC | Y-mAbs Therapeutics, Inc. | 2,244,238 | 5.1% | EDGAR |
| SC 13G/A | 2024-02-06 | ACORN BIOVENTURES, L.P. | Y-mAbs Therapeutics, Inc. | 1,159,966 | 2.7% | EDGAR |
| SC 13G/A | 2024-01-26 | BlackRock Inc. | Y-mAbs Therapeutics, Inc. | 2,917,080 | 6.7% | EDGAR |
| SC 13G | 2023-04-03 | ACORN BIOVENTURES, L.P. | Y-mAbs Therapeutics, Inc. | 977,142 | 2.2% | EDGAR |
| SC 13G/A | 2023-02-14 | HBM Healthcare Investments (Cayman) Ltd. | Y-mAbs Therapeutics, Inc. | 3,813,853 | 8.7% | EDGAR |
| SC 13G | 2023-02-14 | WG Biotech ApS | Y-mAbs Therapeutics, Inc. | 4,178,465 | 9.6% | EDGAR |
| SC 13G | 2023-02-09 | VANGUARD GROUP INC | Y-mAbs Therapeutics, Inc. | 2,258,254 | 5.2% | EDGAR |
| SC 13G/A | 2023-02-01 | BlackRock Inc. | Y-mAbs Therapeutics, Inc. | 2,578,776 | 5.9% | EDGAR |
| SC 13G/A | 2022-04-11 | WELLINGTON MANAGEMENT GROUP LLP | Y-mAbs Therapeutics, Inc. | 1,910,578 | 4.4% | EDGAR |
| SC 13D/A | 2022-02-15 | Sofinnova Venture Partners X, L.P. | Y-mAbs Therapeutics, Inc. | 2,194,278 | 5.0% | EDGAR |
| SC 13G/A | 2022-02-07 | HBM Healthcare Investments (Cayman) Ltd. | Y-mAbs Therapeutics, Inc. | 3,090,954 | 7.1% | EDGAR |
| SC 13G/A | 2022-02-04 | WELLINGTON MANAGEMENT GROUP LLP | Y-mAbs Therapeutics, Inc. | 4,271,382 | 9.8% | EDGAR |
| SC 13G/A | 2022-02-03 | BlackRock Inc. | Y-mAbs Therapeutics, Inc. | 2,767,360 | 6.3% | EDGAR |
| SC 13G/A | 2021-07-12 | WELLINGTON MANAGEMENT GROUP LLP | Y-mAbs Therapeutics, Inc. | 4,448,610 | 10.2% | EDGAR |
| SC 13G/A | 2021-02-12 | HBM Healthcare Investments (Cayman) Ltd. | Y-mAbs Therapeutics, Inc. | 2,130,373 | 5.3% | EDGAR |
| SC 13G/A | 2021-02-04 | WELLINGTON MANAGEMENT GROUP LLP | Y-mAbs Therapeutics, Inc. | 2,439,809 | 6.0% | EDGAR |
| SC 13G | 2021-02-02 | BlackRock Inc. | Y-mAbs Therapeutics, Inc. | 2,418,580 | 6.0% | EDGAR |